Navigation Links
TPI Provides Updates on Jiangchuan Macrolide Facility
Date:9/15/2011

CHENGDU, China, Sept. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that its 250-ton capacity Jiangchuan Macrolide facility (JCM) is scheduled for the manufacturing environmental assessment in late September.

An environmental impact assessment is an evaluation of the possible positive or negative impact of a project that may have on the environment, including the natural, social and economic aspects. The JCM manufacturing environmental assessment is to examine whether the Azithromycin API plant meets various environmental protection standards during its operation. This is a required procedure for the final Good Manufacturing Practice (GMP) certification approval. The environmental assessment will be conducted by the Environmental Assessment Department of Sichuan Province, China.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tianyinpharma.com    

James Jiayuan Tong M.D. Ph.D.
Tel:     +86-28-8551-6696 (Chengdu, China)
          +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA
2. Experis Recognizes National Healthcare IT Week, Provides Tips for ICD-10 Assessment Decision
3. Questcor Provides Updated New Paid Prescription Trends
4. ADVENTRX Provides Update on All Three Pipeline Products
5. Cardium Provides Update on Exchange Listing and Related Business Matters
6. MGT Capital Investments, Inc. Provides Update on Recent Developments
7. Verathon® Introduces the Heartscape™ 3D ECG System with 80-Lead Vest in Europe; Technology Provides More Complete Data to Help Diagnose Acute Myocardial Infarction (MI)
8. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
9. InspireMD Provides Mid-Year Strategic Update
10. Access Pharmaceuticals Provides Second Quarter Update on MuGard Commercial Activities
11. Groupe Athena, Inc. Provides Guidance on Current Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):